Insider · CIK 0001738573
Daniel C. Hillenbrand
director
Files at HI (Hillenbrand, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 18, 2025 | HI Hillenbrand, Inc. | AGrant or award Restricted Stock Units (Deferred Stock Award 2/18/25)derivative | +4,006 | $0.00 | $0 | 4,006 | Feb 20, 2025 |
| Dec 31, 2024 | HI Hillenbrand, Inc. | AGrant or award Restricted Stock Units (Deferred Stock Award 5/10/18)derivative | +7 | $0.00 | $0 | 1,080 | Jan 3, 2025 |
| Dec 31, 2024 | HI Hillenbrand, Inc. | AGrant or award Restricted Stock Units (Deferred Stock Award 2/14/19)derivative | +20 | $0.00 | $0 | 2,860 | Jan 3, 2025 |
| Dec 31, 2024 | HI Hillenbrand, Inc. | AGrant or award Restricted Stock Units (Deferred Stock Award 2/13/20)derivative | +31 | $0.00 | $0 | 4,277 | Jan 3, 2025 |
| Dec 31, 2024 | HI Hillenbrand, Inc. | AGrant or award Restricted Stock Units (Deferred Stock Award 2/11/21)derivative | +21 | $0.00 | $0 | 3,012 | Jan 3, 2025 |
| Dec 31, 2024 | HI Hillenbrand, Inc. | AGrant or award Restricted Stock Units (Deferred Stock Award 2/10/22)derivative | +20 | $0.00 | $0 | 2,783 | Jan 3, 2025 |
| Dec 31, 2024 | HI Hillenbrand, Inc. | AGrant or award Restricted Stock Units (Deferred Stock Award 2/24/23)derivative | +20 | $0.00 | $0 | 2,831 | Jan 3, 2025 |
| Dec 31, 2024 | HI Hillenbrand, Inc. | AGrant or award Restricted Stock Units (Deferred Stock Award 2/20/24)derivative | +22 | $0.00 | $0 | 3,077 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.